Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.355 AUD | +1.43% | -5.33% | +2.90% |
Apr. 18 | Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 | CI |
Apr. 18 | Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.90% | 268M | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Immutep : Receives $2.5 Million Tax Incentive from France